Elisar Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 9.50 Cr
as on 16-11-2024
- Paid Up Capital ₹ 8.38 Cr
as on 16-11-2024
- Company Age 6 Year, 24 Days
- Last Filing with ROC 31 Mar 2023
- Revenue 53.14%
(FY 2023)
- Profit 0.87%
(FY 2023)
- Ebitda 6.45%
(FY 2023)
- Net Worth -38.98%
(FY 2023)
- Total Assets -11.15%
(FY 2023)
About Elisar Life Sciences
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 9.50 Cr and a paid-up capital of Rs 8.38 Cr, as per Ministry of Corporate Affairs (MCA) records.
Ashvin Agarwal and Anosh Agarwal serve as directors at the Company.
- CIN/LLPIN
U33100TN2018PTC125932
- Company No.
125932
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Nov 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Elisar Life Sciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashvin Agarwal  | Director | 26-Nov-2018 | Current |
Anosh Agarwal  | Director | 26-Nov-2018 | Current |
Financial Performance and Corporate Structure Insights of Elisar Life Sciences.
Elisar Life Sciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 53.14% increase. The company also saw a slight improvement in profitability, with a 0.87% increase in profit. The company's net worth observed a substantial decline by a decrease of 38.98%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Elisar Life Sciences?
In 2023, Elisar Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Uber9 Business Process Services Private LimitedActive 10 years 10 daysAnosh Agarwal is a mutual person
Maatrum Technologies And Legal Ventures Private LimitedActive 9 years 8 monthsAnosh Agarwal is a mutual person
Dr Agarwal's Eye Institute Private LimitedActive 47 years 5 monthsAshvin Agarwal is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Elisar Life Sciences?
Elisar Life Sciences has a workforce of 18 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Elisar Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Elisar Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
